Assessing neutralizing antibodies in AAV-mediated gene therapy

Adeno-associated viral (AAV) vectors are a promising method for delivering genes in vivo, but pre-existing neutralizing antibodies (NAb) to AAV proteins present a significant challenge. A thorough understanding of immunogenicity is necessary for effective gene therapies. Svar Life Sciences presents the iLite^® AAV NAb Assay platform, a powerful tool for assessing neutralizing AAV antibodies as it includes the AAV production in the same system, which overcomes the challenges of the AAV production step and reduces the steps on cumbersome cell-based AAV NAb assessment assays.